Dr Reddy

Dr. Reddy’s to focus on complex products as growth driver to offset Revlimid revenue loss

by
The company’s Q3FY25 growth was largely driven by revenues from the NRT portfolio, as well as revenues from the India business and emerging markets.

2025-01-23 22:13:00 : Dr. Reddy’s is focused on a range of complex drugs, including GLP-1 (such as semaglutide), as well as biosimilars and consumer care, to offset the release of its blockbuster Revlimid (Revlimid) next year, an executive said. ) loss of exclusivity. Dr. Reddy CEO Erez Israel said the pharma giant has additional growth … Read more